International Journal of Hematology

, Volume 107, Issue 1, pp 98–104 | Cite as

Autologous hematopoietic stem cell transplantation may improve long-term outcomes in patients with newly diagnosed extranodal natural killer/T-cell lymphoma, nasal type: a retrospective controlled study in a single center

  • Jingwen Wang
  • Liqiang Wei
  • Jin Ye
  • Lei Yang
  • Xin Li
  • Jia Cong
  • Na Yao
  • Xueying Cui
  • Yiping Wu
  • Jing Ding
  • Le Zhang
Original Article

Abstract

Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is a rare disease with a poor prognosis. The long-term effect of autologous hematopoietic stem cell transplantation (auto-HSCT) on ENKTL has been reported occasionally but needs further investigation. In this retrospective study from a single center, 20 ENKTL patients who received induction chemotherapy followed by auto-HSCT ± involved-field radiotherapy (IFRT) ± additional chemotherapy were enrolled as a study group. Another 60 fit ENKTL patients who received induction chemotherapy ± IFRT ± additional chemotherapy were selected as the control group. Baseline characteristics of all patients were well balanced. Our analysis showed that after a median follow-up time of 61.0 months (95% CI 52.3–69.7), the auto-HSCT treated group showed better overall survival (OS) than the control group (p = 0.045). The median OS of the auto-HSCT-treated group was not reached, but that of the control group was 62.0 months. Five-year comparison of OS between the two groups also showed a significant difference (79.3 vs. 52.3%, p = 0.026). We suggest that auto-HSCT treatment, in combination with chemoradiotherapy, may prolong OS and improve the long-term outcomes of fit patients with ENKTL compared to treatment with chemoradiotherapy alone.

Keywords

Natural killer/T-cell lymphoma Autologous hematopoietic stem cell transplantation Chemoradiotherapy 

Notes

Compliance with ethical standards

Funding

This study was supported by Beijing Municipal Science & Technology Commission No. Z151100004015089.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Geneva: WHO Press; 2008.Google Scholar
  2. 2.
    William BM, Armitage JO. International analysis of the frequency and outcome of NK/T-cell lymphoma. Best Pract Res Clin Haematol. 2013;20:23–32.CrossRefGoogle Scholar
  3. 3.
    Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138:429–34.CrossRefPubMedGoogle Scholar
  4. 4.
    Yang QP, Zhang WY, Yu JB, Zhao S, Xu H, Wang WY, et al. Subtype distribution of lymphomas in southwest China: analysis of 6382 cases using WHO classification in a single institution. Diagn Pathol. 2011;6:77.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Tse E, Kwong YL. Nasal NK/T-cell lymphoma: RT, CT, or Both. Blood. 2015;126:1400–1.CrossRefPubMedGoogle Scholar
  6. 6.
    Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood. 2013;121:4997–5005.CrossRefPubMedGoogle Scholar
  7. 7.
    Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, et al. Extranodal natural killer T-cell lymphoma, nasal type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24:612–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Kwong YL. High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies. Bone Marrow Transplant. 2009;44:709–14.CrossRefPubMedGoogle Scholar
  9. 9.
    d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;305:3093–9.CrossRefGoogle Scholar
  10. 10.
    Shustov A. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas. Best Pract Res Clin Haematol. 2013;26:89–99.CrossRefPubMedGoogle Scholar
  11. 11.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.CrossRefPubMedGoogle Scholar
  12. 12.
    Ning F, Wang J, Ye J, Wei L, Qian J, Yang L. Clinical study on patients with nasal NK/T cell lymphoma associated with hemophagocytic syndrome. J Clin Exp Med. 2012;11:92–4.Google Scholar
  13. 13.
    Lee J, Park YH, Kim WS, Lee SS, Ryoo BY, Yang SH, et al. Extranodal nasal-type NK/T cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer. 2005;41:1402–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early-stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002;54:182–90.CrossRefPubMedGoogle Scholar
  15. 15.
    Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103:216–21.CrossRefPubMedGoogle Scholar
  16. 16.
    Micho JM, Mazeron R, Danu A, Lazarovici J, Ghez D, Antosikova A, et al. Concurrent etoposide, steroid, high-dose Ara-C and platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. Eur J Cancer. 2015;51:2386–95.CrossRefGoogle Scholar
  17. 17.
    Yang Y, Zhu Y, Cao JZ, Zhang YJ, Xu LM, Yuan ZY, et al. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. Blood. 2015;126:1424–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Bi XW, Xia Y, Zhang WW, Sun P, Liu PP, Wang Y, et al. Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma. Ann Hematol. 2015;94:1525–33.CrossRefPubMedGoogle Scholar
  19. 19.
    Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 2013;369:1681–90.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Mounier N, Canals C, Gisselbrecht C, Cornelissen J, Foa R, Conde E, et al. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant. 2012;18:788–93.CrossRefPubMedGoogle Scholar
  21. 21.
    Fox CP, Boumendil A, Schmitz N, Finel H, Luan JJ, Sucak G, et al. High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation. Leuk Lymphoma. 2015;56:3295–300.CrossRefPubMedGoogle Scholar
  22. 22.
    Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant. 2008;14:741–7.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106–13.CrossRefPubMedGoogle Scholar
  24. 24.
    Yhim HY, Kim JS, Mun YC, Moon JH, Chae YS, Park Y, et al. Clinical outcomes and prognostic factors of up-front autologous stem cell transplantation in patients with extranodal natural killer/T cell lymphoma. Biol Blood Marrow Transplant. 2015;21:1597–604.CrossRefPubMedGoogle Scholar
  25. 25.
    Lee J, Au WY, Park MJ, Suzumiya J, Nakamura S, Kameoka J, et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant. 2008;14:1356–64.CrossRefPubMedGoogle Scholar
  26. 26.
    Kim HJ, Bang SM, Lee J, Kwon HC, Suh C, Kim HJ, et al. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant. 2006;37:819–24.CrossRefPubMedGoogle Scholar
  27. 27.
    Bang SM, Kim YK, Park YH, Sohn SK, Lee JJ, Cho EK, et al. High-dose therapy and autologous stem cell transplantation in Korean patients with aggressive T/NK-cell lymphoma. Leuk Lymphoma. 2005;46:1599–604.CrossRefPubMedGoogle Scholar
  28. 28.
    Murashige N, Kami M, Kishi Y, Kim SW, Takeuchi M, Matsue K, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol. 2005;130:561–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Kim SJ, Park S, Kang ES, Choi JY, Lim DH, Ko YH, et al. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T cell lymphoma patients. Ann Hematol. 2015;94:71–8.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  • Jingwen Wang
    • 1
    • 2
  • Liqiang Wei
    • 1
    • 2
  • Jin Ye
    • 1
    • 2
  • Lei Yang
    • 1
    • 2
  • Xin Li
    • 1
    • 2
  • Jia Cong
    • 1
    • 2
  • Na Yao
    • 1
    • 2
  • Xueying Cui
    • 1
    • 2
  • Yiping Wu
    • 1
    • 2
  • Jing Ding
    • 1
    • 2
  • Le Zhang
    • 1
    • 2
  1. 1.Department of HematologyBeijing Tongren Hospital, Capital Medical UniversityBeijingChina
  2. 2.Beijing Key Laboratory of Head and Neck Molecular Diagnostic PathologyBeijingChina

Personalised recommendations